× Industry Reports Services Press Release Contact us About us

Asia Pacific Cell Line Development Market Forecast 2027 By Application (Bioproduction, Drug Discovery, Toxicity Testing, Tissue Engineering, Research), By Product (Reagents & Media, Equipment {Incubator, Centrifuge, Bioreactor, Storage Equipment, Microscope}, Accessories & Consumables), By Source (Mammalian, Non-mammalian {Insects, Amphibians}), By Cell Line (Recombinant, Hybridomas, Continuous Cell Line, Primary Cell Line), I Research Report, Country Outlook (Japan, China, India, Australia, South Korea, Malaysia, Indonesia, Thailand, Singapore, Taiwan, Philippines, Vietnam), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share
Published Date: September 2021 | Publisher: Graphical Research Report ID: GR1065 | Delivery : PDF  Request Free Sample

Asia Pacific Cell Line Development Market size valued at USD 939 million in 2020 and is projected to showcase around 13.8% CAGR from 2021 to 2027. Rapidly increasing regulatory authority approval for vaccine development will boost the market demand. Numerous vaccine manufacturers are taking efforts to increase the research and development activities to accelerate their business.

 

Asia Pacific Cell Line Development Market

Get more details on this report - Request Free Sample PDF

Asia Pacific Market, By Product

Reagent & media segment accounted for around USD 500 million in 2020. Reagents and media are used in cell culture, they specially support the growth of cells, microorganism. Amino acids, serum, inorganic salts and other are the source factors that help in cell line development. Increasing use of reagents and media will enhance segment growth.

Asia Pacific Market, By Source

The non-mammalian cell line development market in Asia Pacific is expected to expand at 13.4% CAGR between 2021 and 2027. Non-mammalian cell are those cells in which insects, amphibians are used in biomedical studies or experiments. For example, Drosophila melanogaster is commonly used for experiment. The use of these insects during cell line development will spur the industry demand.

Asia Pacific Market, By Cell Line Type

Asia Pacific Cell Line Development Market, By Cell Line Type

Get more details on this report - Request Free Sample PDF

The continuous cell line development market will exhibit nearly 14% growth rate in Asia Pacific during the forecast timeline. Continuous cell lines are derived from immortalized cells lines, and they are capable of infinite growth. These cell lines are widely used in inexpensive tools for toxicity tests, biological research, and production of biological compounds such as antibodies, therapeutic proteins and vaccines. Increasing demand such biological compounds will accelerate the segment growth.

Asia Pacific Market, By Application

Drug discovery segment is set to register growth of 13% till 2027. In last few years, pharmaceutical and biotechnology industry is taking efforts for novel drug discovery to cure patient health and improve the market position. 3D cell culture technique is a fundamental technique in drug discovery and medical research. Researchers use this technique in preclinical drug discovery. Growing demand of drug discovery in biotechnology industry will boost the segment expansion.

Asia Pacific Market, By Country

China cell line development market held more than 22% revenue share in 2020. Biologics are one of the key products in China that include monoclonal antibodies especially designed to treat cancer and autoimmune disease. Chinese industry players are developing new cell lines to propel the market growth. Furthermore, regulatory approvals and government support will drive the market demand.

Competitive Industry Landscape

Prominent players in the Asia Pacific cell line development market are GE Healthcare, Lonza Group, Corning, WuXi AppTec, Sartorius, Selexis, EuBiologics, GVK BIO, Patheon, Samsung Biologics, Thermo Fisher Scientific, and Sigma-Aldrich Corporation (Merck).

These industry participants are involved in new product launches, strategic collaboration, mergers and acquisitions, definitive agreement to strengthen the market position. For instance, in August 2020, Samsung Biologics launched a S-CHOice cell line technology. The technology will enhance cell viability and produce high quality cell lines.
 

Frequently Asked Question(FAQ) :

The market size for cell line development in Asia Pacific was reached USD 939 million in 2020 and should grow at over 13.8% CAGR up to 2027 led by growing regulatory approvals for vaccine development.
The reagents & media segment of Asia Pacific industry generated USD 500 million in 2020 owing to large-scale application in cell culture.
The market share for non-mammalian cell line development in Asia Pacific could expand at more than 13.4% CAGR up to 2027.
Asia Pacific industry size from continuous cell line development could grow at a 14% CAGR over 2021-2027 due to extensive use in toxicity tests, biological research, and production of antibodies, vaccines, and therapeutic proteins.
The industry share for cell line development in Asia Pacific from drug discovery applications will grow at over 13% CAGR till 2027 owing to continuous drug development efforts.
China held more than 22% of APAC industry share in 2020 owing to growing government support and regulatory approvals.

Premium Report

Have questions?
  • Inquire Before Buying
  • Why Choose us?

    • on-time delivery On-Time Delivery

      We commit to on-time delivery of reports to keep you ahead.

    • assured quality Assured Quility

      With a wide network of industry experts and trained in-house analysts, we assure best service quality.

    • Custom Research Service

      We offer research services to meet specific client requirements and provide them with actionable insights on target markets.

    • payment security Payment Security

      Our safe payment gateway gives you full control of your personal data, at all times.

    Connect with our sales team

     1-800-986-6917

     [email protected]